Mycetoma News and Research

RSS

WHO and Sanofi sign new agreement to sustain specific efforts to eliminate NTDs

The World Health Organization (WHO) and Sanofi – one of the world's leading pharmaceutical companies – have signed a new agreement for donations of medicines to sustain specific efforts to eliminate neglected tropical diseases (NTDs).

16 Dec 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

Study: Neglecting development of therapeutics may repeat history and replicate vaccine inequality

A new policy report released today by the global non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) highlights how the development of therapeutics has been relatively neglected in the global response to COVID-19 and warns that with the few treatment innovations available principally in high-income countries, we risk repeating history and replicating the vaccine inequality that has become a defining characteristic of this global pandemic.

6 Aug 2021

ANTICOV clinical trial to test new treatment for people with mild-to-moderate COVID-19 in Africa

The ANTICOV clinical trial, conducted in 13 African countries, has started the recruitment of participants to test a new drug combination, nitazoxanide + ciclesonide, to treat people with mild-to-moderate COVID-19 before their cases become severe.

27 Apr 2021

World Malaria Day 2021: An interview with Sir Brian Greenwood

News-Medical interviews Sir Brian Greenwood about raising awareness for malaria during the COVID-19 pandemic and achieving elimination of the disease.

23 Apr 2021

World Health Organization, Sanofi sign new agreement to eliminate neglected tropical diseases

15 Dec 2020

Novartis and DNDi to partner on development of new oral treatment for visceral leishmaniasis

Novartis and the Drugs for Neglected Diseases initiative, a not-for-profit research and development organization, have signed a collaboration and license agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world's leading parasitic killers.

25 Feb 2020

International consortium to receive BRL 43.5 million for discovering drugs to treat neglected diseases

In the search for new drugs to treat neglected diseases and malaria, researchers at the University of Campinas and University of Sao Paulo will assemble a team of scientists in a global collaboration network co-funded by the São Paulo Research Foundation, the Drugs for Neglected Diseases initiative and the Medicines for Malaria Venture.

26 Nov 2019

'African eye worm' hampers efforts to eliminate river blindness, study shows

Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.

20 Nov 2019

People successfully treated for visceral leishmaniasis can still infect others, study confirms

The results of an innovative "infectivity" study conducted by the Drugs for Neglected Diseases initiative and the International Centre for Diarrhoeal Disease Research, Bangladesh confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known as post-kala-azar dermal leishmaniasis.

22 Jul 2019

Scientists study immune molecules inside mycetoma grains

Mycetoma is a common neglected disease caused by either fungi or bacteria which organize themselves into grains—areas of inflammation surrounded by a collagen capsule.

From PLOS ONE 12 Jul 2019

Shorter treatment for Chagas disease found to be effective and safer than standard treatment

A two-week treatment course for adult patients with chronic Chagas disease showed, when compared to placebo, similar efficacy and significantly fewer side effects than the standard treatment duration of eight weeks, according to the results of a clinical trial in Bolivia led by the Drugs for Neglected Diseases initiative.

14 Mar 2019

New drug for sleeping sickness approved in the Democratic Republic of Congo

Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT), more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC).

31 Jan 2019

Combination therapy shows high efficacy in treating people with leishmaniasis and HIV

The results of clinical trials conducted in Ethiopia by the Drugs for Neglected Diseases initiative, in partnership with Médecins Sans Frontières, the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis, a group of patients who have historically suffered from poor treatment options.

18 Jan 2019

EMA recommends first all-oral treatment to tackle deadly sleeping sickness

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness.

16 Nov 2018

Clinical trial begins to find better treatment for chronic cases of PKDL in Africa

A clinical trial to find a better treatment for severe or chronic cases of post kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan.

12 Sep 2018

Clinical study to find improved treatment for visceral leishmaniasis starts in eastern Africa

A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis has begun in eastern Africa, within the new Afri-KA-DIA Consortium with funding from The European & Developing Countries Clinical Trials Partnership.

13 Apr 2018

Open Pharma drug discovery project aims to develop new treatments for mycetoma

The MycetOS project was launched today by the University of Sydney, Erasmus MC, and the Drugs for Neglected Diseases initiative to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.

6 Feb 2018

GHIT Fund announces US$16.7 million to support development of new drugs, vaccines and diagnostics

The Global Health Innovative Technology Fund, a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced US$16.7 million to support development of new compounds for fighting malaria and tuberculosis, a leishmaniasis vaccine and drug, and a treatment for a long-ignored flesh-eating infection.

31 Oct 2017

First-ever clinical study for effective treatment of mycetoma begins in Sudan

The first-ever double-blind, randomized clinical trial for an effective treatment for the severely neglected disease mycetoma has enrolled its first patient at the Mycetoma Research Centre in Khartoum, Sudan.

19 Jun 2017